Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Phathom Pharmaceuticals, Inc. (PHAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Second Quarter 2023 Results"
07/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/30/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation"
05/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Phathom intends to use the net proceeds from the proposed offer...",
"Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130.7 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 1,668,750 shares of common stock at the public offering price, less underwriting discounts and commiss..."
05/23/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports First Quarter 2023 Results"
04/04/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/28/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
02/09/2023 8-K Other Events  Interactive Data
01/09/2023 8-K Other Events  Interactive Data
01/03/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
09/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/04/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates"
05/27/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
05/03/2022 8-K Other Events  Interactive Data
04/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/01/2022 8-K Quarterly results
02/09/2022 8-K Other Events  Interactive Data
01/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan",
"Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan"
11/08/2021 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates"
10/18/2021 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/27/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy